1
|
Tsang RSW, Deceuninck G, Meilleur C, Zhou J, Lefebvre B, De Wals P. Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex. J Infect 2024; 88:106163. [PMID: 38670267 DOI: 10.1016/j.jinf.2024.106163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 04/11/2024] [Accepted: 04/17/2024] [Indexed: 04/28/2024]
Abstract
OBJECTIVE To identify recent trends in invasive meningococcal diseases (IMD) in Quebec, Canada, with a focus on MenY cases and MenY strains. METHODS IMD cases and MenY strains from January 1, 2015 to August 11, 2023 were analyzed for clonal analysis and prediction of susceptibility to MenB vaccines. MenY strains of ST-23 CC from Quebec were analyzed with global MenY strains by core-genomic multi-locus sequence typing (cg-MLST). RESULTS Since 2015 the serogroup distribution of IMD in Quebec has shifted from predominantly MenB to mainly MenY, with most (80.9 %) of the latter belonging to ST-23 CC. The median age of MenY cases due to ST-23 CC were statistically younger than MenY cases due to non-ST-23 CC. MenY of ST-23 CC showed genetic diversity and the major genetic cluster were similar to the Swedish Y1 strain. The increase in invasive MenY disease in Quebec was due to a sub-clade of Lineage 23.1 which caused an elevated proportion of severe disease in young adults. CONCLUSION The increase in invasive MenY disease in Quebec, Canada was driven by the expansion of a sub-clade of Lineage 23.1 in young adults. Currently available quadrivalent A,C,W,Y-conjugate meningococcal vaccines were predicted to provide protection against these strains.
Collapse
Affiliation(s)
- Raymond S W Tsang
- Vaccine Preventable Bacterial Disease, Reference Science and Surveillance Directorate, National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
| | - Genevieve Deceuninck
- Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec - Université Laval, Québec City, Québec, Canada; Direction des risques biologiques, Institut National de Santé Publique du Québec, Québec City, Québec, Canada
| | - Courtney Meilleur
- Vaccine Preventable Bacterial Disease, Reference Science and Surveillance Directorate, National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Jianwei Zhou
- Vaccine Preventable Bacterial Disease, Reference Science and Surveillance Directorate, National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Brigitte Lefebvre
- Laboratoire de santé publique du Québec, Institut nationale de sante publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada
| | - Philippe De Wals
- Department of Social and Preventive Medicine, Laval University, Québec City, Québec, Canada
| |
Collapse
|
2
|
Birrell MT, Strachan J, Holmes NE, Stevens K, Howden BP, Franklin LJ, Ivan M, Kwong JC. Clinical manifestations of invasive meningococcal disease in Victoria with the emergence of serogroup W and serogroup Y Neisseria meningitidis. Intern Med J 2021; 51:390-397. [PMID: 32043702 DOI: 10.1111/imj.14771] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 02/05/2020] [Accepted: 02/05/2020] [Indexed: 01/17/2023]
Abstract
BACKGROUND Historically, Australian cases of invasive meningococcal disease (IMD) have been most frequently caused by Neisseria meningitidis serogroup B, but recently an increase in cases due to serogroup W (MenW) and serogroup Y (MenY) has occurred. AIM To determine whether clinical manifestations of IMD have changed due to increased incidence of MenW and MenY. METHODS We performed a retrospective review of IMD cases notified to the Department of Health and Human Services in Victoria, Australia. We compared the period between January 2013 and June 2015 (defined as P1) immediately before the increase in MenW and MenY was noted, with the equal time period of July 2015 to December 2017 (P2), when this increase was observed. RESULTS IMD was notified more frequently in P2 than P1 (1.24 vs 0.53 per 100 000 person-years, P < 0.001). IMD cases in P2 were older (46 vs 19 years, P < 0.001), and more likely due to MenW (92/187, 49.2% vs 11/80, 13.8%, P < 0.001) or MenY (31/187, 16.6% vs 4/80, 5.0%, P = 0.01). IMD cases from P2 were more likely bacteraemic (151/187, 80.7% vs 55/80, 68.8%, P = 0.04), while meningitis (68/187, 36.4% vs 41/80, 51.3%, P = 0.03) and rash (65/181, 35.9% vs 45/78, 57.7%, P = 0.002) were less frequent. Intensive care unit admission rates and in-hospital mortality were unchanged. CONCLUSION Alongside an increase in IMD in Victoria, the proliferation of cases of MenW and MenY occurred in older patients, and were more often identified through bacteraemia rather than meningitis or purpura fulminans. Clinicians should be aware of these changes to facilitate earlier identification and treatment of IMD.
Collapse
Affiliation(s)
- Michael T Birrell
- Victorian Department of Health and Human Services, Melbourne, Victoria, Australia.,Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia
| | - Janet Strachan
- Victorian Department of Health and Human Services, Melbourne, Victoria, Australia
| | - Natasha E Holmes
- Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia
| | - Kerrie Stevens
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne, Melbourne, Victoria, Australia
| | - Benjamin P Howden
- Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.,Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne, Melbourne, Victoria, Australia
| | - Lucinda J Franklin
- Victorian Department of Health and Human Services, Melbourne, Victoria, Australia
| | - Mihaela Ivan
- Victorian Department of Health and Human Services, Melbourne, Victoria, Australia
| | - Jason C Kwong
- Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.,Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Hong E, Barret AS, Terrade A, Denizon M, Antona D, Aouiti-Trabelsi M, Deghmane AE, Parent du Châtelet I, Levy-Bruhl D, Taha MK. Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France. J Infect 2018; 76:149-158. [DOI: 10.1016/j.jinf.2017.10.015] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 10/17/2017] [Accepted: 10/27/2017] [Indexed: 12/24/2022]
|
4
|
Cordeiro SM, Cardoso CW, de Araújo LG, Ribeiro LE, Azevedo J, Silva RDCV, Dos Reis MG, Ko AI, Reis JN. Dissemination of the ST-103 clonal complex serogroup C meningococci in Salvador, Brazil. Microbes Infect 2018; 20:19-24. [PMID: 28962886 DOI: 10.1016/j.micinf.2017.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/21/2017] [Accepted: 09/21/2017] [Indexed: 12/01/2022]
Abstract
Invasive meningococcal disease (IMD) is a major public health problem worldwide. An epidemic of serogroup C (NmC) IMD occurred in 2010 in the city of Salvador. In this study, we describe the antigenic and genetic characterization of meningococcal isolates collected from meningitis cases in Salvador from 2001 to 2012. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were performed for the analysis of IMD isolates. A total of 733 cases were identified, and the serogroup was determined for 391 (53.0%) of these. Most cases were caused by NmC (53%) or B (47%). The most prevalent strains were B:4,7:P1.19,15 (32.9%; 129/391) and C:23:P1.14-6 (28.6%; 112/391). Based on PFGE/MLST analysis, 71.3% (77/108 PFGE-tested isolates) clustered as two clones of sequence type ST-3779 and ST-3780, both belonging to the ST-103 clonal complex. ST-3779 has been detected in Salvador since 1996 and together with ST-3780 became predominant after 2005. There was a predominance of C:23:P1.14-6, ST-3779/3780 in Salvador during the period of 2007-2012, establishing a major clonal lineage, which remained in the community for a long time; this has serious implications for public health, particularly in terms of prevention and control strategies of IMD.
Collapse
Affiliation(s)
- Soraia Machado Cordeiro
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil; School of Pharmacy, Federal University of Bahia, Rua Barão do Jeremoabo, n° 147, Ondina, Salvador, 40170-115, Brazil
| | - Cristiane Wanderley Cardoso
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil; Municipal Secretary of Health of Salvador, Rua da Grécia, 3, Comercio, Salvador 40010-010, Brazil
| | - Lorena Galvão de Araújo
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil
| | - Luis Eduardo Ribeiro
- School of Pharmacy, Federal University of Bahia, Rua Barão do Jeremoabo, n° 147, Ondina, Salvador, 40170-115, Brazil
| | - Jailton Azevedo
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil
| | | | - Mitermayer Galvão Dos Reis
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil
| | - Albert Icksang Ko
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College Street, New Haven, CT 06520-8034, USA
| | - Joice Neves Reis
- Gonçalo Moniz Research Institute, Oswaldo Cruz Foundation, Brazil Ministry of Health, Rua Waldemar Falcão, 141, Candeal, Salvador 40296-710, Brazil; School of Pharmacy, Federal University of Bahia, Rua Barão do Jeremoabo, n° 147, Ondina, Salvador, 40170-115, Brazil.
| |
Collapse
|
5
|
Borrow R, Lee JS, Vázquez JA, Enwere G, Taha MK, Kamiya H, Kim HM, Jo DS. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative. Vaccine 2016; 34:5855-5862. [PMID: 27780631 DOI: 10.1016/j.vaccine.2016.10.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 09/24/2016] [Accepted: 10/11/2016] [Indexed: 10/20/2022]
Abstract
The Global Meningococcal Initiative (GMI) is a global expert group that includes scientists, clinicians, and public health officials with a wide range of specialties. The purpose of the Initiative is to promote the global prevention of meningococcal disease (MD) through education, research, and cooperation. The first Asia-Pacific regional meeting was held in November 2014. The GMI reviewed the epidemiology of MD, surveillance, and prevention strategies, and outbreak control practices from participating countries in the Asia-Pacific region.Although, in general, MD is underreported in this region, serogroup A disease is most prominent in low-income countries such as India and the Philippines, while Taiwan, Japan, and Korea reported disease from serogroups C, W, and Y. China has a mixed epidemiology of serogroups A, B, C, and W. Perspectives from countries outside of the region were also provided to provide insight into lessons learnt. Based on the available data and meeting discussions, a number of challenges and data gaps were identified and, as a consequence, several recommendations were formulated: strengthen surveillance; improve diagnosis, typing and case reporting; standardize case definitions; develop guidelines for outbreak management; and promote awareness of MD among healthcare professionals, public health officials, and the general public.
Collapse
Affiliation(s)
- Ray Borrow
- Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, UK.
| | - Jin-Soo Lee
- Inha University Hospital, Incheon, Republic of Korea.
| | | | | | | | - Hajime Kamiya
- National Institute of Infectious Diseases, Infectious Disease Surveillance Center, Tokyo, Japan.
| | - Hwang Min Kim
- Yonsei University, Wonju Severance Christian Hospital, Wonju, Republic of Korea.
| | - Dae Sun Jo
- Chonbuk National University Hospital, Jeonju, Republic of Korea.
| | | |
Collapse
|
6
|
Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study. PLoS One 2015; 10:e0123734. [PMID: 25874777 PMCID: PMC4395143 DOI: 10.1371/journal.pone.0123734] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 02/25/2015] [Indexed: 11/25/2022] Open
Abstract
Background During a citywide epidemic of serogroup C meningococcal disease in Salvador in 2010, Brazil, the state government initiated mass vaccination targeting two age groups with high attack rates: individuals aged <5 years and 10–24 years. More than 600,000 doses of meningococcal serogroup C conjugate vaccines were administered. We performed a case-control study to evaluate vaccine uptake, document vaccine effectiveness and identify reasons for non-vaccination. Methods and Findings Population-based surveillance identified patients with laboratory-confirmed invasive meningococcal C (MenC) disease during 2010. Information on MenC vaccination was obtained from case patients and age-matched individuals from the same neighborhoods. MenC vaccine effectiveness was estimated based on the exact odds ratios obtained by conditional logistic regression analysis. Of 51 laboratory-confirmed cases of serogroup C meningococcal disease among patients <5 and 10–24 years of age 50 were included in the study and matched with 240 controls. Overall case-fatality was 25%. MenC vaccine coverage among controls increased from 7.1% to 70.2% after initiation of the vaccination campaign. None of the 50 case patients but 70 (29.2%) of the 240 control individuals, including 59 (70.2%) of 84 matched with cases from the period after MenC vaccination, had received at least one MenC vaccine dose. Overall effectiveness of MenC was 98% with a lower 95% exact confidence limit of 89%. Conclusions MenC vaccines administered during the meningococcal epidemic were highly effective, suggesting that rapid vaccine uptake through campaigns contributed to control of meningococcal disease.
Collapse
|
7
|
Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data. THE LANCET. INFECTIOUS DISEASES 2014; 14:805-12. [DOI: 10.1016/s1473-3099(14)70806-0] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
8
|
Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013; 11:17. [PMID: 24016339 PMCID: PMC3848799 DOI: 10.1186/1478-7954-11-17] [Citation(s) in RCA: 251] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Accepted: 09/06/2013] [Indexed: 11/16/2022] Open
Abstract
Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial in providing protection. Available epidemiological data from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control collections and published articles are included in this review, as well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt; many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence countries include many from Europe and the Americas. Priority countries for vaccine intervention are high- and moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of IMD are needed in countries where this is not known, particularly in South- East Asia and Eastern Mediterranean regions, so evidence-based decisions about the use of meningococcal vaccines can be made.
Collapse
Affiliation(s)
- Rabab Z Jafri
- Department of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, Pakistan
| | - Asad Ali
- Department of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, Pakistan
| | | | - Carol Tevi-Benissan
- Immunisation, Vaccines and Biologicals, World Health Organisation, Geneva, Switzerland
| | - David Durrheim
- School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
- Health Protection, Hunter New England Area, Wallsend, Australia
| | - Juhani Eskola
- Finnish National Institute for Health and Welfare (THL), Helsinki, Finland
| | - Florence Fermon
- International vaccination working group, Médécins Sans Frontières, Paris, France
| | - Keith P Klugman
- Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
- Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand and Medical Research Council, Johannesburg, South Africa
| | - Mary Ramsay
- Immunisation Department at the Health Protection Agency, Centre for Infections in Colindale, London, UK
| | - Samba Sow
- Center for Vaccine Development, Ministry of Health, Bamako, Mali
- School of Medicine, University of Maryland, Baltimore, MD, USA
| | - Shao Zhujun
- Institute for Communicable Disease Control and Prevention, Beijing, People’s Republic of China
| | - Zulfiqar A Bhutta
- Department of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, Pakistan
| | - Jon Abramson
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| |
Collapse
|
9
|
Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS One 2012; 7:e44102. [PMID: 22952888 PMCID: PMC3431326 DOI: 10.1371/journal.pone.0044102] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 07/30/2012] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Published data on the epidemiology of meningococcal disease in Latin America and the Caribbean region is scarce and, when available, it is often published in Spanish and/or in non-peer-reviewed journals, making it difficult for the international scientific community to have access. METHODS Laboratory data on 4,735 Neisseria meningitidis strains was collected and reported by the National Reference Laboratories in 19 Latin American countries and the Caribbean Epidemiology Centre (CAREC) between 2006 and 2010 as part of the work carried out by the SIREVA II network. Serogroup and MIC to penicillin, rifampin and chloramphenicol were determined. RESULTS Isolates were mainly obtained from patients <5 years, but each year around 25% of isolates came from adult patients. Serogroup distribution was highly variable among countries. Serogroup C was the main cause of disease in Brazil; the majority of disease seen in the Southern cone was caused by serogroup B, but serogroup W135 strains have increased in recent years. In the Andean and Mexico, Central America and Caribbean regions, serogroups B and C were equally present, and serogroup Y was frequently isolated. Isolates were generally susceptible to chloramphenicol, penicillin and rifampin, but almost 60% of isolates characterized in Southern cone countries presented intermediate resistance to penicillin. Five rifampin-resistant isolates have been isolated in Uruguay and Brazil. CONCLUSIONS Serogroup distribution is highly variable among countries, but some geographic structuring can be inferred from these data. Epidemiological and laboratory data are scarce among Andean and Mexico, Central America and Caribbean countries. Evaluation and implementation of corrective measures on disease surveillance and reporting systems and the implementation of molecular diagnostic techniques and molecular characterization on meningococcal isolates are advised.
Collapse
|
10
|
The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape. Epidemiol Infect 2012; 141:447-58. [PMID: 22877581 PMCID: PMC3566594 DOI: 10.1017/s0950268812001689] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Meningococcal disease is mostly endemic in Latin America, with periodic occurrences of outbreaks and epidemics over the last few decades. This literature review summarizes the available epidemiological data for this region between 1945 and 2010. Incidence rates and serogroup distribution differ from country to country and over time. Serogroups A, B, and C have all been major causes of meningococcal disease since the 1970s. In the last decade serogroups W135 and Y may now be emerging in certain countries, with serogroup A virtually disappearing. Although progress has been made in improving and coordinating the surveillance of invasive disease, the uniformity and quality of reported data reflect the fact that the current surveillance systems focus on passive rather than active reporting, hence the reliability of data may vary between countries. Consideration of vaccination policies to control meningococcal disease can only be made with a sufficient understanding of the changing epidemiology in the region.
Collapse
|
11
|
Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law DKS, De Wals P, Tsang RSW. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012; 50:1545-51. [PMID: 22337990 PMCID: PMC3347115 DOI: 10.1128/jcm.06835-11] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Accepted: 02/09/2012] [Indexed: 11/20/2022] Open
Abstract
In the era after the introduction of the meningococcal serogroup C conjugate vaccine, from 1 January 2003 to 31 December 2010, serogroup B meningococci were the major cause of invasive meningococcal disease in the province of Québec, Canada, being responsible for 72% of all meningococcal disease cases. Of the 334 invasive serogroup B Neisseria meningitidis strains analyzed, 53.9% belonged to the ST-269 clonal complex (CC). Since it first emerged in 2003, the percentage of invasive serogroup B isolates that belonged to the ST-269 CC had increased from 35% in 2003 to 76% in 2010. Among the 180 meningococci in the ST-269 CC, 91.7% belonged to a single ST (ST-269). The most common PorA genotypes identified in the ST-269 CC were (i) VR1 19-1, VR2 15-11, VR3 36 (84%) and (ii) VR1 18-7, VR2 9, VR3 35-1 (9%). Cases of invasive disease due to the ST-269 CC were commonly found in those aged 11 to 19 years (30.5%) and 20 to 40 years (25.5%). Meningococci of the ST-269 CC were uncommon in other Canadian provinces. In contrast to the ST-269 CC, invasive serogroup B meningococci that belonged to the ST-41/44 CC were much more diverse genetically. However, one ST (ST-571), which is uncommon in the United States, accounted for 35% of all cases due to this CC. The current finding suggests that the ST-269 clone may indeed represent an emerging hypervirulent clone of meningococci.
Collapse
Affiliation(s)
- Jianwei Zhou
- Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
| | - Brigitte Lefebvre
- Laboratorie de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec
| | - Saul Deng
- Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
| | - Rodica Gilca
- Institut National de Santé Publique du Québec, Centre de Recherche du CHUL-CHUQ, Québec, Québec
- Department de Medecine Sociale et Preventive de I'Université Laval, Québec, Québec, Canada
| | - Genevieve Deceuninck
- Institut National de Santé Publique du Québec, Centre de Recherche du CHUL-CHUQ, Québec, Québec
- Department de Medecine Sociale et Preventive de I'Université Laval, Québec, Québec, Canada
| | - Dennis K. S. Law
- Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
| | - Philippe De Wals
- Institut National de Santé Publique du Québec, Centre de Recherche du CHUL-CHUQ, Québec, Québec
- Department de Medecine Sociale et Preventive de I'Université Laval, Québec, Québec, Canada
| | - Raymond S. W. Tsang
- Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
| |
Collapse
|
12
|
Sáfadi MAP, Cintra OAL. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010; 32:263-71. [PMID: 20406604 DOI: 10.1179/016164110x12644252260754] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
OBJECTIVE Meningococcal disease continues to be a serious public health concern, being associated with high morbidity and mortality rates in many countries from Latin America. In addition to discussing recent changes in the epidemiology of meningococcal disease in the region, we also analyse the development and potential impact of new vaccines on the prevention of meningococcal disease. METHODS MEDLINE, SciELO, LILACS and websites of the national Ministries of Health databases were searched using the terms meningococcal disease, meningococcal epidemiology, Neisseria meningitidis, meningococcal vaccines and the name of Latin America countries, from 1998 to 2008, with emphasis on review articles, clinical trials and epidemiological studies. RESULTS Epidemiology of meningococcal disease in Latin America is characterized by marked differences from country to country. The overall incidence of meningococcal disease per year varied from less than 0.1 cases per 100,000 inhabitants in countries like Mexico to two cases per 100,000 inhabitants in Brazil. The highest age-specific incidence of meningococcal disease occurred in infants less than 1 year of age. Serogroups B and C were responsible for the majority of cases reported, but the emergence of serogroups W135 and Y was reported in some countries. Serogroup A disease is now rare in Latin America. DISCUSSION Although a few countries have established meningitis surveillance programs, the information is not uniform, and the quality of the reported data is poor in the majority of the region. The availability of new effective meningococcal conjugate vaccines and promising protein-based vaccine candidates against meningococcus B highlights the importance of a better understanding of the true burden of meningococcal disease in Latin America and also the need for cost-effectiveness studies before incorporating the new meningococcal vaccines to national immunization programs.
Collapse
|
13
|
Elias J, Schouls LM, van de Pol I, Keijzers WC, Martin DR, Glennie A, Oster P, Frosch M, Vogel U, van der Ende A. Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany. Emerg Infect Dis 2010; 16:465-72. [PMID: 20202422 PMCID: PMC3322024 DOI: 10.3201/eid1603.091102] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
An emerging serogroup B clone can be prevented by vaccines. Emergence of serogroup B meningococci of clonal complex sequence type (ST) 41/44 can cause high levels of disease, as exemplified by a recent epidemic in New Zealand. Multiplication of annual incidence rates (3.1 cases/100,000 population) of meningococcal disease in a defined German region, the city of Aachen and 3 neighboring countries (Greater Aachen) prompted us to investigate and determine the source and nature of this outbreak. Using molecular typing and geographic mapping, we analyzed 1,143 strains belonging to ST41/44 complex, isolated from persons with invasive meningococcal disease over 6 years (2001–2006) from 2 German federal states (total population 26 million) and the Netherlands. A spatially slowly moving clone with multiple-locus variable-number tandem repeat analysis type 19, ST42, and antigenic profile B:P1.7–2,4:F1–5 was responsible for the outbreak. Bactericidal activity in serum samples from the New Zealand MeNZB vaccination campaign confirmed vaccine preventability. Because this globally distributed epidemic strain spreads slowly, vaccination efforts could possibly eliminate meningococcal disease in this area.
Collapse
|
14
|
Barroso DE, Carvalho D, Casagrande S, Rebelo M, Soares V, Zahner V, Solari C, Nogueira S. Microbiological epidemiological history of meningococcal disease in Rio de Janeiro, Brazil. Braz J Infect Dis 2010. [DOI: 10.1016/s1413-8670(10)70051-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Vogel U, Elias J, Claus H, Frosch M. Labordiagnostik vonNeisseria meningitidisaus der Sicht des Nationalen Referenzzentrums für Meningokokken / Laboratory diagnosis ofNeisseria meningitidisfrom the viewpoint of the German Reference Laboratory. ACTA ACUST UNITED AC 2009. [DOI: 10.1515/jlm.2009.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Muscat M, Spiteri G, Calleja N, Haider J, Gray SJ, Melillo JM, Mamo J, Cuschieri P. Invasive meningococcal disease in Malta: an epidemiological overview, 1994-2007. J Med Microbiol 2009; 58:1492-1498. [PMID: 19589903 DOI: 10.1099/jmm.0.011312-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Since 1996, Malta has experienced an upsurge of invasive meningococcal disease (IMD) following an almost 30 year period with a negligible number of annually reported cases. We reviewed the 233 IMD cases notified during a 14 year period (1994-2007), and analysed epidemiological and laboratory surveillance data. The crude incidence per 100,000 inhabitants peaked in 2000 at 8.1 [95 % confidence interval (CI) 5.7-11.6] and again in 2006 at 8.9 (95 % CI 6.4-12.4), thereby placing Malta amongst the countries with the highest incidence of the disease in Europe. Of the total cases, 137 (59 %) were confirmed and 30 (13 %) were classified as probable. However, 66 cases (28 %) had no laboratory evidence of the disease and were classified as possible. Information on the serogroup was available for 114 cases. Serogroup B formed the largest proportion (76 %, n=87) followed by serogroup C (16 %, n=18). B : 4 : P1.19,15 strains (n=46) predominated throughout the study period since their first identification in 1998. With 28 deaths attributed to IMD, the overall case fatality rate was 12 %. Apart from stressing the importance of maintaining high vigilance for IMD, our findings underscore the importance of enhancing laboratory surveillance of the disease, including characterization of the meningococci. Until vaccines against a broad range of serogroup B meningococci become available for universal use, the main methods of control remain the early treatment of cases and the prevention of secondary cases.
Collapse
Affiliation(s)
- Mark Muscat
- Department of Epidemiology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark
| | - Gianfranco Spiteri
- Infectious Disease Prevention and Control Unit, Department of Health Promotion and Disease Prevention, 5B The Emporium, C. de Brocktorff Street, Msida MSD 1421, Malta
| | - Neville Calleja
- Directorate of Health Information and Research, 95 G'Mangia Hill, G'Mangia PTA 1313, Malta
| | - Julie Haider
- Bacteriology Laboratory, Department of Pathology, Mater Dei Hospital, Msida MSD 2090, Malta
| | - Stephen J Gray
- Meningococcal Reference Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, UK
| | - Jackie Maistre Melillo
- Infectious Disease Prevention and Control Unit, Department of Health Promotion and Disease Prevention, 5B The Emporium, C. de Brocktorff Street, Msida MSD 1421, Malta
| | - Julian Mamo
- Department of Public Health, Mater Dei Hospital, Medical School, University of Malta, Msida MSD 2090, Malta
| | - Paul Cuschieri
- Bacteriology Laboratory, Department of Pathology, Mater Dei Hospital, Msida MSD 2090, Malta
| |
Collapse
|
17
|
von Gottberg A, du Plessis M, Cohen C, Prentice E, Schrag S, de Gouveia L, Coulson G, de Jong G, Klugman K. Emergence of Endemic Serogroup W135 Meningococcal Disease Associated with a High Mortality Rate in South Africa. Clin Infect Dis 2008; 46:377-86. [DOI: 10.1086/525260] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
18
|
Abstract
Meningococcus, an obligate human bacterial pathogen, remains a worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal conjugate vaccines for serogroups A, C, Y, W-135, and broadly effective serogroup B vaccines are on the horizon, which could eliminate the organism as a major threat to human health in industrialised countries in the next decade. The crucial challenge will be effective introduction of new meningococcal vaccines into developing countries, especially in sub-Saharan Africa, where they are urgently needed.
Collapse
Affiliation(s)
- David S Stephens
- Emory University School of Medicine, Atlanta, GA, USA; Research Service (151I), Atlanta VA Medical Center, Decatur, GA, USA.
| | | | - Petter Brandtzaeg
- Departments of Paediatrics and Clinical Chemistry, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway
| |
Collapse
|
19
|
Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007; 186:108-9. [PMID: 17309394 DOI: 10.5694/j.1326-5377.2007.tb00828.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2006] [Accepted: 12/18/2006] [Indexed: 11/17/2022]
|
20
|
Brooks R, Woods CW, Benjamin DK, Rosenstein NE. Increased Case‐Fatality Rate Associated with Outbreaks ofNeisseria meningitidisInfection, Compared with Sporadic Meningococcal Disease, in the United States, 1994–2002. Clin Infect Dis 2006; 43:49-54. [PMID: 16758417 DOI: 10.1086/504804] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2005] [Accepted: 03/13/2006] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Outbreaks of meningococcal disease are infrequent but important public health events. We characterize outbreak-associated cases in the United States and compare them with sporadic disease. METHODS Outbreaks of meningococcal disease that occurred during the period of 1 July 1994 through 30 June 2002 were identified through state health departments, Centers for Disease Control and Prevention records, and a review of newspapers and the medical literature. Cases associated with outbreaks were compared with sporadic cases identified through population-based surveillance. RESULTS We identified 69 outbreaks of Neisseria meningitidis infection (median, 9.5 outbreaks per year; range, 3-14 outbreaks per year), which involved 229 patients from 30 states. Forty-three (62%) of the outbreaks involved N. meningitidis serogroup C, 17 (25%) involved serogroup B, and 9 (13%) involved serogroup Y. Twenty-five outbreaks (36%) occurred in communities, and 44 (64%) were organization based, including 12 that occurred in colleges and universities, 19 that occurred in primary and secondary schools, and 8 that occurred in nursing homes. Vaccination campaigns (with the A/C/Y/W-135 meningococcal polysaccharide vaccine) were conducted for 31 outbreaks (28 involving serogroup C and 3 involving serogroup Y). After controlling for age, serogroup, and clinical presentation, outbreak-associated cases were associated with a higher case-fatality rate than were sporadic cases (21% vs. 11%; odds ratio, 3.3; 95% confidence interval, 2.0-5.5). CONCLUSIONS Outbreaks remain an important but infrequent public health issue, representing <2% of all cases of meningococcal disease. However, given the increased case-fatality rate found among outbreak-related cases of N. meningitidis infection, additional investigation of factors that favor the transmission and virulence of outbreak-related strains is warranted.
Collapse
Affiliation(s)
- Richard Brooks
- Duke University School of Medicine, Durham, North Carolina, USA
| | | | | | | |
Collapse
|
21
|
Bille E, Zahar JR, Perrin A, Morelle S, Kriz P, Jolley KA, Maiden MCJ, Dervin C, Nassif X, Tinsley CR. A chromosomally integrated bacteriophage in invasive meningococci. ACTA ACUST UNITED AC 2005; 201:1905-13. [PMID: 15967821 PMCID: PMC2212043 DOI: 10.1084/jem.20050112] [Citation(s) in RCA: 128] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Cerebrospinal meningitis is a feared disease that can cause the death of a previously healthy individual within hours. Paradoxically, the causative agent, Neisseria meningitidis, is a common inhabitant of the human nasopharynx, and as such, may be considered a normal, commensal organism. Only in a small proportion of colonized people do the bacteria invade the bloodstream, from where they can cross the blood–brain barrier to cause meningitis. Furthermore, most meningococcal disease is caused by bacteria belonging to only a few of the phylogenetic groups among the large number that constitute the population structure of this genetically variable organism. However, the genetic basis for the differences in pathogenic potential remains elusive. By performing whole genome comparisons of a large collection of meningococcal isolates of defined pathogenic potential we brought to light a meningococcal prophage present in disease-causing bacteria. The phage, of the filamentous family, excises from the chromosome and is secreted from the bacteria via the type IV pilin secretin. Therefore, this element, by spreading among the population, may promote the development of new epidemic clones of N. meningitidis that are capable of breaking the normal commensal relationship with humans and causing invasive disease.
Collapse
Affiliation(s)
- Emmanuelle Bille
- Institut National de la Santé et de la Recherche Medicale U570, Faculté de Médecine Necker, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
BACKGROUND Randomised trials carried out over two decades ago showed that the polysaccharide vaccine prevented serogroup A meningococcal meningitis. Subsequent non-randomised studies, however, suggested significant variations in the age-specific duration of protection among young children. OBJECTIVES The aim of the review was to determine the effect of polysaccharide serogroup A vaccine for preventing serogroup A meningococcal meningitis. The specific objectives were to assess the age-specific effects of the vaccine, the effect of booster doses in children under five years of age, and the duration of protection in children and adults. SEARCH STRATEGY In 2004, the review was updated. The following databases were searched for records of new trials: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2004); MEDLINE (January 1966 to November Week 1 2004); and EMBASE (January 1990 to September 2004). SELECTION CRITERIA The first stage of the review included randomised trials. The second stage included non- randomised studies that addressed specific outcomes not answered by the randomised trials. DATA COLLECTION AND ANALYSIS One reviewer assessed the methodological quality of the randomised trials and two reviewers independently identified and assessed the non-randomised studies. Of the twelve eligible Randomized trials, four were excluded because of the high risk of bias in assessing vaccine efficacy. Data from the trials were pooled using the Exact method to assess vaccine efficacy at one, two and three years post vaccination. Of the 15 non-randomised studies, only two addressed the specific objectives not answered by the randomised trials but were assessed to be at high risk of bias. MAIN RESULTS The protective effect within the first year of vaccination was consistent across the randomised trials, and the summary vaccine efficacy was 95% (95% confidence interval (CI) 87% to 99%). Protection extended into the second and third year after vaccination but the results did not attain statistical significance. The vaccine was protective in Finnish children aged 3 months to five years. The latter was also the only trial that assessed the effect of a booster dose in children under two years of age but lacked power to yield statistically significant results. The vaccine was protective in one- to five-year old children in developing countries (Nigeria and Sudan) but the age-specific efficacy in strata between one and five years of age could not be determined. AUTHORS' CONCLUSIONS For the first year after vaccination, the polysaccharide serogroup A vaccine was strongly protective against serogroup A meningococcal meningitis in participants over five years of age. It was also protective beyond the first year after vaccination in this age group but the level of vaccine efficacy could not be determined with precision. Children aged one to five years in developing countries were also protected but the level of efficacy in this age group could not be determined. While the vaccine was strongly protective among children aged three months to five years in developed countries the level of efficacy across age strata within this age group could not be determined. The number of children aged under two years was too small to draw conclusions on the protective effect of a booster dose of vaccine.
Collapse
Affiliation(s)
- M Patel
- National Centre for Epidemiology and Population Health, Australian National University, C/R Eggleston and Mills Roads, Canberra, ACT, Australia, 2600.
| | | |
Collapse
|
23
|
Miller MA, Shahab CK. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. PHARMACOECONOMICS 2005; 23:333-43. [PMID: 15853434 DOI: 10.2165/00019053-200523040-00004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Outbreaks of meningococcal disease have caused devastation worldwide. Effective vaccines have not been used routinely, due to perceived limitations of the duration of effectiveness as well as immunogenicity when administered during infancy. Given the sporadic nature of outbreaks, the optimal use of these vaccines to control both short-term epidemic and endemic meningococcal disease has been the subject of much debate. Seven economic studies on the use of polysaccharide vaccination strategies help to highlight the relevant epidemiological and economic issues surrounding the decisions for their use. Five of these studies were based in Africa, the region where annual incidence rates can be several orders of magnitude greater than the rest of the world. These studies demonstrated that vaccination against meningococcal disease during outbreak situations is suboptimal given the inability to rapidly immunise populations in a timely fashion in resource-poor areas. However, depending on the disease incidence and the ability to deliver vaccines, the polysaccharide vaccine can be cost effective for preventive strategies when given prior to the start of outbreaks, either through presumptive vaccination or through a modified routine delivery strategy. Economic analyses of mass immunisation campaigns and modelled routine vaccination suggest that routine use of meningococcal vaccines for preventive strategies could be within the range of cost-effective public health interventions in those regions of the world where meningococcal disease is endemic. This includes the meningococcal belt of Africa, the Sahelian region.
Collapse
Affiliation(s)
- Mark A Miller
- Division on International Epidemiology and Population Studies, Fogarty Internatonal Center, National Institutes of Health, Building 16, 16 Center Drive, Bethesda, MD 20892-6705, USA.
| | | |
Collapse
|
24
|
Abstract
Carbohydrates in the form of capsular polysaccharides and/or lipopolysaccharides are the major components on the surface of bacteria. These molecules are important virulence factors in many bacteria isolated from infected persons. Immunity against these components confers protection against the disease. However, developing vaccines based on polysaccharides is difficult and several problems have to be solved. First of all, most of the bacterial polysaccharides are T-lymphocyte independent antigens. Anti-polysaccharide immune response is characterised by lack of T-lymphocyte memory, isotype restriction and delayed ontogeny. Children below 2 years of age and elderly respond poorly to polysaccharide antigens. Secondly, the wide structural heterogeneity among the polysaccharides within and between species is also a problem. Thirdly, some bacterial polysaccharides are poor immunogens in humans due to their structural similarities with glycolipids and glycoproteins present in man. The T-lymphocyte independent nature of a polysaccharide may be overcome by conjugating the native or depolymerised polysaccharide to a protein carrier. Such neoglycoconjugates have been proven to be efficient in inducing T-lymphocyte dependent immunity and to protect both infants as well as elderly from disease. Another approach to circumvent the T-lymphocyte independent property of polysaccharides is to select peptides mimicking the immunodominant structures. Several examples of such peptides have been described.
Collapse
Affiliation(s)
- Andrej Weintraub
- Karolinska Institute, Department of Laboratory Medicine, Division of Clinical Bacteriology, Huddinge University Hospital, S-141 86 Stockholm, Sweden.
| |
Collapse
|
25
|
McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn AB, Pacheco AGF, Razeq J, Harrison LH. Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland. Emerg Infect Dis 2004; 10:451-6. [PMID: 15109412 PMCID: PMC3322775 DOI: 10.3201/eid1003.020611] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Epidemic meningococcal infection is generally caused by single clones; whether nonepidemic increases in infection are clonal is unknown. We studied the molecular epidemiology of meningococcal infection during a period that the incidence increased in two age groups. Serogroup C and Y meningococcal isolates were analyzed by pulsed-field gel electrophoresis and multilocus sequence typing. From 1992 to 1999, 96.4% (27/28) of serogroup C isolates from persons 15-24 years of age were in clonal group 1, compared with 65.6% (21/32) of isolates from persons < or =14 years, and 64.3% (9/14) of isolates from adults > or =25 years (p < or = 0.01). The proportion of clonal group 2 serogroup Y strains increased from 7.7% (1/13) in 1992 to 1993 to 52.0% (13/25) in 1998 to 1999 (p < 0.01). The nonepidemic age-specific increases in serogroup C meningococcal infection in Maryland were clonal in nature and the changes in serogroup Y incidence were associated with a shift in the genotypes of strains causing invasive disease.
Collapse
Affiliation(s)
- M. Catherine McEllistrem
- University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, USA
| | - John A. Kolano
- University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Margaret A. Pass
- Johns Hopkins University Bloomberg School of Hygiene and Public Health, Baltimore, Maryland, USA
| | - Dominique A. Caugant
- World Health Organization Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway
| | - Aaron B. Mendelsohn
- University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA
| | | | - Jafar Razeq
- Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA
| | - Lee H. Harrison
- University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, USA
- Johns Hopkins University Bloomberg School of Hygiene and Public Health, Baltimore, Maryland, USA
| | | |
Collapse
|
26
|
Abstract
Neisseria meningitidis is a major cause of bacterial meningitis and sepsis. Polysaccharide-protein conjugate vaccines for prevention of group C disease have been licensed in Europe. Such vaccines for prevention of disease caused by groups A (which is associated with the greatest disease burden worldwide), Y, and W135 are being developed. However, conventional approaches to develop a vaccine for group B strains, which are responsible for most cases in Europe and the USA, have been largely unsuccessful. Capsular polysaccharide-based vaccines can elicit autoantibodies to host polysialic acid, whereas the ability of most non-capsular antigens to elicit broad-based immunity is limited by their antigenic diversity. Many new membrane proteins have been discovered during analyses of genomic sequencing data. These antigens are highly conserved and, in mice, elicit serum bactericidal antibodies, which are the serological hallmark of protective immunity in man. Therefore, there are many promising new vaccine candidates, and improved prospects for development of a broadly protective vaccine for group B disease, and for control of all meningococcal disease.
Collapse
Affiliation(s)
- Luis Jódar
- Vaccine Development and Quality and Safety of Biologicals, World Health Organization, Geneva, Switzerland.
| | | | | | | |
Collapse
|
27
|
Abstract
The past century has seen the use of a number of vaccines for prevention and control of meningococcal disease with varied success. The use of polysaccharide vaccines for the control of outbreaks of serogroup C infections in teenagers and young adults and epidemic serogroup A disease has been established for 30 years and an effective protein-polysaccharide conjugate vaccine against serogroup C was introduced into the UK infant immunisation schedule in 2000. The next generation of these glycoconjugate vaccines will be on the shelf soon, eventually offering the prospect of eradication of serogroups A, C, Y and W135 through routine infant immunisation. Despite these exciting prospects, serogroup B meningococci still account for a majority of infections in industrialised nations but development of safe, immunogenic and effective serogroup B meningococcal vaccines has been an elusive goal. Outer membrane vesicle vaccines for B disease are already used in some countries, and will likely be used more widely in the next few years, but efficacy for endemic disease in children has so far been disappointing. However, the innovations arising from the availability of the meningococcal genome sequence, public and scientific interest in the disease and recent pharmaceutical company investment in development of serogroup B vaccines may have started the countdown to the end of meningococcal infection in children.
Collapse
Affiliation(s)
- S L Morley
- Department of Paediatrics, Imperial College School of Medicine, St Mary's Campus, Norfolk Place, London W2 1PG, UK.
| | | |
Collapse
|
28
|
Moreno-Civantos A, Díaz-Jiménez J, Domínguez-Berjón MF. [Shared surveillance: meningococcal disease vs influenza]. GACETA SANITARIA 2000; 14:422-8. [PMID: 11270167 DOI: 10.1016/s0213-9111(00)71908-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To analyse the association between the behavior of meningococcal disease and influenza, using for this purpose population statistics for Spain for the period of 1964 to 1997. METHODS Ecological study of the incidence of meningococcal disease and influenza in Spain from 1964 to 1997, inclusive. The study used weekly statistical data for these diseases supplied by the Compulsory Disease Reporting System (Enfermedades de Declaración Obligatoria, EDO). The deterministic component of the meningococcal disease and influenza series was studied by means of spectral analysis based on the Fast Fourier Transformation, and the non-deterministic component was studied using the ARIMA model. The Box-Jenkins method was used for pre-bleaching the series, and a cross-correlation was subsequently established between the residuals in order to detect the presence of any significant correlations between the meningococcal disease and influenza series. RESULTS During the period from 1964 to 1997, the week that showed, on average, the greatest number of cases for the season was week 7 in the case of meningococcal disease and week 6 in the case of influenza. Spectral analysis of the meningococcal disease and influenza series clearly demonstrated the annual periodicity of both series, and periodicity of nearly 11 years for meningococcal disease and slightly over 10 years for influenza. When cross-correlation is established after prebleaching the series, positive correlations are obtained in the results of lags 0, 1, 2, and 3. Introducing influenza as an exogenous variable in the multivariate model of meningococcal disease corroborates these results. There was a statistically significant relationship between the two processes during the same week and with a three-week lapse. CONCLUSIONS By means of a methodology not previously applied to this subject, and by the use of prolonged time-span, country-comprehensive population statistics (which includes several epidemics waves), an association was shown to exist between meningococcal disease and influenza. This suggests the need for the surveillance of the two processes in an interrelated manner.
Collapse
Affiliation(s)
- A Moreno-Civantos
- Servicio Salud Pública Area 2, Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid
| | | | | |
Collapse
|
29
|
Robbins JB, Schneerson R, Gotschlich EC. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 2000; 19:945-53. [PMID: 11055594 DOI: 10.1097/00006454-200010000-00001] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- J B Robbins
- National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | |
Collapse
|
30
|
Harrison LH. Preventing meningococcal infection in college students. Clin Infect Dis 2000; 30:648-51. [PMID: 10770724 DOI: 10.1086/313741] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2000] [Indexed: 11/03/2022] Open
Abstract
The incidence of invasive meningococcal disease in adolescents and young adults of high school and college age has recently increased in the United States. Recent studies indicate that certain groups of college students are at increased risk. This has led to the recent Advisory Committee Immunization Practices recommendation that college freshman dormitory residents be provided information about meningococcal infection and the benefits of vaccination. Future studies will need to focus on the potential vaccine prevention of the increased risk of meningococcal infection in persons of high school age, particularly as new conjugate meningococcal vaccines become available.
Collapse
Affiliation(s)
- L H Harrison
- Infectious Diseases Epidemiology Research Unit, Departments of Medicine and Epidemiology, University of Pittsburgh School of Medicine PA 15261, USA.
| |
Collapse
|
31
|
Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000. [PMID: 10627495 DOI: 10.1128/cmr.13.1.144-166.2000] [Citation(s) in RCA: 201] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The only natural reservoir of Neisseria meningitidis is the human nasopharyngeal mucosa. Depending on age, climate, country, socioeconomic status, and other factors, approximately 10% of the human population harbors meningococci in the nose. However, invasive disease is relatively rare, as it occurs only when the following conditions are fulfilled: (i) contact with a virulent strain, (ii) colonization by that strain, (iii) penetration of the bacterium through the mucosa, and (iv) survival and eventually outgrowth of the meningococcus in the bloodstream. When the meningococcus has reached the bloodstream and specific antibodies are absent, as is the case for young children or after introduction of a new strain in a population, the ultimate outgrowth depends on the efficacy of the innate immune response. Massive outgrowth leads within 12 h to fulminant meningococcal sepsis (FMS), characterized by high intravascular concentrations of endotoxin that set free high concentrations of proinflammatory mediators. These mediators belonging to the complement system, the contact system, the fibrinolytic system, and the cytokine system induce shock and diffuse intravascular coagulation. FMS can be fatal within 24 h, often before signs of meningitis have developed. In spite of the increasing possibilities for treatment in intensive care units, the mortality rate of FMS is still 30%. When the outgrowth of meningococci in the bloodstream is impeded, seeding of bacteria in the subarachnoidal compartment may lead to overt meningitis within 24 to 36 h. With appropriate antibiotics and good clinical surveillance, the mortality rate of this form of invasive disease is 1 to 2%. The overall mortality rate of meningococcal disease can only be reduced when patients without meningitis, i.e., those who may develop FMS, are recognized early. This means that the fundamental nature of the disease as a meningococcus septicemia deserves more attention.
Collapse
|
32
|
van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13:144-66, table of contents. [PMID: 10627495 PMCID: PMC88937 DOI: 10.1128/cmr.13.1.144] [Citation(s) in RCA: 235] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The only natural reservoir of Neisseria meningitidis is the human nasopharyngeal mucosa. Depending on age, climate, country, socioeconomic status, and other factors, approximately 10% of the human population harbors meningococci in the nose. However, invasive disease is relatively rare, as it occurs only when the following conditions are fulfilled: (i) contact with a virulent strain, (ii) colonization by that strain, (iii) penetration of the bacterium through the mucosa, and (iv) survival and eventually outgrowth of the meningococcus in the bloodstream. When the meningococcus has reached the bloodstream and specific antibodies are absent, as is the case for young children or after introduction of a new strain in a population, the ultimate outgrowth depends on the efficacy of the innate immune response. Massive outgrowth leads within 12 h to fulminant meningococcal sepsis (FMS), characterized by high intravascular concentrations of endotoxin that set free high concentrations of proinflammatory mediators. These mediators belonging to the complement system, the contact system, the fibrinolytic system, and the cytokine system induce shock and diffuse intravascular coagulation. FMS can be fatal within 24 h, often before signs of meningitis have developed. In spite of the increasing possibilities for treatment in intensive care units, the mortality rate of FMS is still 30%. When the outgrowth of meningococci in the bloodstream is impeded, seeding of bacteria in the subarachnoidal compartment may lead to overt meningitis within 24 to 36 h. With appropriate antibiotics and good clinical surveillance, the mortality rate of this form of invasive disease is 1 to 2%. The overall mortality rate of meningococcal disease can only be reduced when patients without meningitis, i.e., those who may develop FMS, are recognized early. This means that the fundamental nature of the disease as a meningococcus septicemia deserves more attention.
Collapse
Affiliation(s)
- M van Deuren
- Department of Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands.
| | | | | |
Collapse
|
33
|
Affiliation(s)
- H Peltola
- Helsinki University Central Hospital, Hospital for Children and Adolescents, Finland
| |
Collapse
|
34
|
Abstract
BACKGROUND Controlled trials over two decades ago showed that the polysaccharide vaccine prevented meningococcal meningitis. Subsequent observational studies suggested variations in the level and duration of protection, particularly among young children. OBJECTIVES To determine the effect of polysaccharide serogroup A vaccine for preventing serogroup A meningococcal meningitis. SEARCH STRATEGY MEDLINE and the Cochrane Controlled Trials Register. SELECTION CRITERIA Randomised and other prospective controlled trials. DATA COLLECTION AND ANALYSIS One reviewer collected data and assessed the methodologic quality of the trials. Data were pooled using the Exact method to assess vaccine efficacy at one, two and three years post-vaccination. MAIN RESULTS The protective effect within the first year was consistent across all eight trials, including one with participants exclusively under six years of age (in Finland); overall vaccine efficacy was 95% (Exact 95% CI 87%, 99%). The Finnish trial lacked statistical power to assess the effect of a booster dose given to children less than 18 months old. In the three other trials that included children less than six years old (one in Sudan and two in Nigeria), none of the vaccinated children developed meningitis, but the statistical significance of this finding was undetermined. Protection extended into the second (in two studies) and third (in one study) years after vaccination, but these results were also not statistically significant. REVIEWER'S CONCLUSIONS When compared with current recommendations, the methodological quality and relative incompleteness of the published reports could arguably render the trials invalid for this review. However, it was unlikely that the results of the trials in such diverse settings would have been biased towards a strong and consistent protective effect. Immunogenicity trials were not included in this review. Stage two of the review will assess the vaccine effect from observational studies.
Collapse
Affiliation(s)
- M Patel
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT 0200, Australia.
| | | |
Collapse
|
35
|
Lindberg AA. Polyosides (encapsulated bacteria). COMPTES RENDUS DE L'ACADEMIE DES SCIENCES. SERIE III, SCIENCES DE LA VIE 1999; 322:925-32. [PMID: 10646085 DOI: 10.1016/s0764-4469(00)87188-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The polysaccharide capsule which surrounds bacterial species such as Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis and Salmonella typhi is a potent virulence factor by protecting the bacteria from phagocytosis. The host responds with antibody production and specific antibodies plus complement binding to the capsule facilitate opsonization of the micro-organism, which is phagocytized and eliminated. Purified capsular polysaccharides elicit T-independent antibody responses without a memory function, but are often poorly immunogenic in infants where much of the invasive H. influenzae type b (Hib) and pneumococcal infections is seen. Therefore purified polysaccharides have found limited use as vaccines. However, covalent linkage of the capsular polysaccharide, or fractions thereof, to immunogenic carrier proteins creates glycoconjugates which are T-dependent antigens and which elicit antibodies also in infants and which prime for boosting either with the glycoconjugate or the capsular polysaccharide. In the last decade Hib glycoconjugate vaccines have been successfully introduced and in countries with very high immunization coverage the disease has been virtually eliminated and a decline of over 95% has been seen in countries with slightly lower vaccine rates. World-wide use of Hib glycoconjugate vaccines offers the possibility of elimination of invasive Hib disease. Pneumococcal (11 serotypes with coverage of approximately 85% of invasive disease), meningococcal (A, C, W 135, Y but not B) and S. typhi glycoconjugates are in advanced development and offer the prospect of being as successful as the Hib glycoconjugates.
Collapse
|
36
|
Abstract
The polysaccharide capsule which surrounds bacterial species like Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, is a potent virulence factor. It protects the bacterium from phagocytosis, but capsule specific antibodies plus complement binding to the capsule opsonise the organism for phagocytosis and elimination. Purified capsules elicit T-independent antibody responses without a memory function, and are often poorly immunogenic in infants where much of invasive H. influenzae type b (Hib) and pneumococcal infection is seen. Covalent linkage of the polysaccharide, or fractions thereof, to immunogenic carrier proteins creates glycoconjugates which are T-dependent antigens and which prime for boosting either with the glycoconjugate or the capsular polysaccharide; During the 1990s, four Hib glycoconjugate vaccines have been introduced and in countries that have vaccinated the majority of children, the success has been stunning. In countries with very high immunization coverage the disease has been virtually eliminated and, to a decline of over 95% in countries with slightly lower vaccine rates. Worldwide use of Hib glycoconjugate vaccines offers the possibility of elimination of invasive Hib disease. Pneumococcal (11 serotypes with coverage of approximately 85% of invasive disease) and meningococcal (A, C, W 135, Y but not B) glycoconjugates are in pre-registration phases and offer the prospect of being as successful as the Hib glycoconjugates.
Collapse
Affiliation(s)
- A A Lindberg
- Pasteur Mérieux Connaught, 1541 Avenue Marcel Mérieux 69280, Marcy l'Etoile, France
| |
Collapse
|
37
|
Abstract
A comprehensive review of all major agents causing bacterial meningitis--meningococcus of the groups A, B, C, W135, and Y, pneumococcus, and Haemophilus influenzae type B (Hib)--is done in terms of preventing them by chemoprophylaxis or vaccination. Some evidence suggests that the group B meningococcal disease may also be very likely preventable by a vaccine that is already available. Excellent Hib conjugates use a technique that is expected to revolutionize immunoprophylaxis against most meningococcal and pneumococcal diseases in the near future. Unfortunately, the high cost of conjugate vaccines restricts their use in many poor countries.
Collapse
Affiliation(s)
- H Peltola
- Department of Infectious Diseases, Helsinki University Central Hospital, Finland
| |
Collapse
|
38
|
Aboal Viñas JL, Farjas Abadía P, Zubizarreta Alberdi R, Hervada Vidal X, Malvar Pintos A, Amigo Quintana M, Fernández Arribas S, Moreno Molinero MF, Taboada Rodríguez JA. [Meningococcal C disease epidemic in Galicia 1996: the decision making process]. GACETA SANITARIA 1999; 13:62-9. [PMID: 10217678 DOI: 10.1016/s0213-9111(99)71323-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In this article we describe the decision making process used to choose the best alternative for bringing under control an epidemic of meningococcal C disease, which occurred in Galicia in 1996. In the decision making process, we used a methodology which consisted on the identification and definition of a problem, in order to identify alternative solutions and to select one, and finally implement and evaluate it. The health problem was detected studying the data obtained from a survey conducted following an outbreak of meningococcal C disease in february 1995 and from the active epidemiological surveillance system created thereafter. Because this was a new, complex and severe problem, with far-reaching social consequences, critical for our organization, and with long-term implications, and because it was considered important to take the decision as objectively as possible and to clearly explain it, the methodology chosen to solve the problem was a non-programmed, multicriteria making decision process, carried out by a working group using a criterion weighting approach. This working group was created within the General Directorate of Public Health, composed of specialist and of people responsible for the different areas involved. The working group put into practice the different steps of the methodology. The assessment criteria and their respective weights were: effect (efficacy measured by the number of cases we could have prevented if the alternatives were applied in the previous season) 40%; cost (in millions of pesetas) 15%; acceptability (acceptance of and response to each strategy from different groups: general population, health care professionals, other Administrations with competency in Public Health) 30%; and coherence (adherence to the currently accepted strategies for disease control in other countries)15%. When these criteria were applied to the ten alternatives considered, a score was obtained for each one of them. The highest scoring alternative corresponded to the massive vaccination of the total population of Galicia between 18 months and 19 years of age.
Collapse
Affiliation(s)
- J L Aboal Viñas
- Dirección General de Salud Pública, Xunta de Galicia, Santiago de Compostela, A Coruña, 15771, España
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Barroso DE, de Carvalho DM, Nogueira SA, Solari CA. [Meningococcal disease: epidemiology and control of secondary cases]. Rev Saude Publica 1998; 32:89-97. [PMID: 9699352 DOI: 10.1590/s0034-89101998000100014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Epidemiological features of meningococcal disease described as from the second half of the 80's inclusive, have motivated a revision of current guidelines for sporadic disease and outbreak control. The increase of disease among teenagers and linked cases involving schools are the two most significant aspects that have prompted the revision of control measures. Vaccination routines and advice for the disease management of clusters are also relevant features recently revised. This present paper describes the management and some epidemiological features of secondary cases.
Collapse
Affiliation(s)
- D E Barroso
- Departamento de Medicina Tropical, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
| | | | | | | |
Collapse
|
40
|
Robbins JB, Towne DW, Gotschlich EC, Schneerson R. "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350:880-2. [PMID: 9310615 DOI: 10.1016/s0140-6736(97)03227-3] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- J B Robbins
- Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2720, USA
| | | | | | | |
Collapse
|
41
|
Farjas P, Aboal JL, Zubizarreta R, Hervada J, Malvar A, González J, Amigo M, Taboada JA, Fernández S, Moreno MJ, Gestal JJ. [Analysis of the management of the vaccination campaign in 1996-1997 against meningococcus C in Galicia]. GACETA SANITARIA 1997; 11:242-51. [PMID: 9494289 DOI: 10.1016/s0213-9111(97)71303-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
This paper describes the process to design and plan a vaccination campaign against group C N. Meningitidis developed in the Autonomous Community of Galicia between December 9, 1996 and January 31, 1997. We also analyse the results of this process in terms of management results, vaccine coverage and preliminary estimates of effectiveness. A Work group was established, made up of professionals in charge of different intervention areas. A person was designated in charge of the whole campaign and a follow-up and information system was created. The work plan consisted of daily meetings for follow-up, co-ordination and task distribution; and periodical meetings with primary health care and peripheral public health coordinators. Strategies of implantation--in order to make sure the campaign accessibility and acceptability; of budget and of communication with health workers, inhabitants and mass media were developed. Up to 100 tasks were identified to develop the technical information and logistic activities: mailings, meetings, leaflets, ...; purchasing of 584.980 doses of vaccine, supplying to 715 vaccination points (1040 deliveries); problem solving and intervention recording. A vaccination coverage of 85% was achieved, with notification of 8 adverse reactions and 6 errors in the administration of the vaccine (34 children affected). The strategy chosen for the design and planning of the campaign has proven to be effective and valid and sufficient to achieve the final goals, in due time and without problems of misinformation, shortage of vaccine or lack of participation of professionals or people. Mistakes due to incorrect administration of the vaccine, management problems, rupture of the cold chain or recording failures were minimal and accidental.
Collapse
|
42
|
Andersen J, Backer V, Voldsgaard P, Skinhøj P, Wandall JH. Acute meningococcal meningitis: analysis of features of the disease according to the age of 255 patients. Copenhagen Meningitis Study Group. J Infect 1997; 34:227-35. [PMID: 9200030 DOI: 10.1016/s0163-4453(97)94255-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Clinical and laboratory features of acute meningococcal meningitis according to age were studied in 255 patients. Whereas males accounted for three out of five patients aged 0-4 years, females accounted for three out of four patients older than 50 years of age. All patients had clinical signs of nuchal rigidity and fever. Patients older than 30 years of age had less frequent petechiae (62%) than younger patients (81%). Furthermore, elderly patients above 50 years of age were prone to an obtunded mental state and a prolonged disease course with fever. Without relation to age, 2/3 had purulent meningitis and 2/3 had marked peripheral leucocytosis (> 15 x 10(9) cells/l); 90% of patients had at least one of these findings. The cellular inflammatory response in peripheral blood indicated a bacterial aetiology in > 95% of the cases. More than 80% of children and adults had abnormal CSF biochemical findings, but the level of protein and the glucose ratio (CSF/serum) were positively and negatively correlated to increasing age of the patient, respectively: thus, in children these biochemical markers may be unreliable in the differentiation between a bacterial and non-bacterial aetiology. Thrombocytopenia (< 100.000 x 10(9)/I) was not associated with age, though the lowest platelet count was found in elderly patients. The case fatality rate was 7.5%, but neither age, sex nor sign of septicaemia was associated with fatality. Thrombocytopenia, a lowered coagulation index (< 0.5, factors II, VII, X), a moderate anaemia (haemoglobin < 11 g/dl), an obtunded mental state and a history of convulsions were poor prognostic factors; only anaemia was independently correlated to fatality so this should be considered as an important prognostic marker in the acute phase of meningococcal meningitis.
Collapse
Affiliation(s)
- J Andersen
- Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark
| | | | | | | | | |
Collapse
|
43
|
|
44
|
Kennedy NJ, Duncan AW. Acute meningococcaemia: recent advances in management (with particular reference to children). Anaesth Intensive Care 1996; 24:197-216. [PMID: 9133195 DOI: 10.1177/0310057x9602400212] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- N J Kennedy
- Paediatric Intensive Care Unit, Princess Margaret Hospital, Perth, , Australia
| | | |
Collapse
|
45
|
Lengeler C, Kessler W, Daugla D. The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination? Acta Trop 1995; 59:211-22. [PMID: 7572427 DOI: 10.1016/0001-706x(95)00081-o] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A large outbreak of meningococcal meningitis (Serogroup A) occurred in southern Chad in 1990. We describe the epidemic in the town of Sarh, where a mass vaccination against meningococcal meningitis had taken place two years before, in 1988 (estimated coverage: 66%). Early warning that an epidemic was imminent was given at the end of February, following more than 15 recorded cases per 100,000 population on 3 consecutive weeks. This threshold proved to be adequate to predict the outbreak. A total of 721 cases were recorded at Sarh hospital and at a nearby health centre. Direct agglutination tests confirmed that Neisseria meningitis serogroup A was the only causative agent. The overall incidence rate in this population of 80,000 was 0.9%. The highest weekly incidence rate was 186 cases per 100,000 population. The mean age of the patients was 12.6 years and age-specific incidence rates ranged from 0.23% to 1.42%. The male/female sex ratio was 1.36. Overall, the mortality among hospitalized patients was 7.9%. Mortality increased during the epidemic. The major risk factor for dying was the delay until reaching hospital. Only 4 out of 29 interviewed parents said that their child had been vaccinated two years before. Among adult patients this proportion was 12/38 (32%). Because of the small numbers and because of the impossibility to check the vaccination records it was not possible to assess precisely the impact of earlier mass vaccination. However, the previous mass vaccination did not prevent this major epidemic and its impact is likely to have been unimportant.
Collapse
Affiliation(s)
- C Lengeler
- Institut Tropical Suisse, N'Djaména, Chad
| | | | | |
Collapse
|
46
|
de Gouvêa DS, Nobre FF. [Occurrence of meningococcal meningitis in a Southern region of Brazil, from 1974 to 1980, using the point event model]. Rev Saude Publica 1991; 25:103-11. [PMID: 1784966 DOI: 10.1590/s0034-89101991000200004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Descriptive statistical techniques and point event model methods were used to investigate the temporal series of cases of meningococcal meningitis which occurred in 100 municipalities in the Rio Grande do Sul State, Brazil, during the period 1974-1980. The data were grouped by epidemiological state (epidemic or endemic), and separated into 5 groups according to the municipal population. The number of cases of the disease notified weekly was analysed by means of incidence coefficients, with the purpose of studying the epidemic threshold for the state. The time interval between events was analysed in the light of their probability density functions and expected density functions, with the objective of studying the relationship and dependences among events. The analysis of the epidemic threshold suggests that there should not be only one threshold value for detection of outbreak of the disease throughout the state. Analysis of the expected density function extracted from inter-event intervals of the epidemic state showed a correlational structure indicating dependence between events occurring up to 14 weeks apart. No significant correlation for the endemic state, taking as reference model the shuffled version of the original intervals, was observed.
Collapse
Affiliation(s)
- D S de Gouvêa
- Departamento de Circuitos Elétricos da Faculdade de Engenharia da Universidade Federal de Juiz de Fora, MG, Brasil
| | | |
Collapse
|
47
|
Affiliation(s)
- G L Gilbert
- Department of Microbiology/Infectious Diseases, Royal Children's Hospital, Melbourne
| |
Collapse
|
48
|
Salih MA, Ahmed HS, Osman KA, Kamil I, Palmgren H, Hofvander Y, Olcén P. Clinical features and complications of epidemic group A meningococcal disease in Sudanese children. ANNALS OF TROPICAL PAEDIATRICS 1990; 10:231-8. [PMID: 1703738 DOI: 10.1080/02724936.1990.11747436] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The clinical presentation and laboratory features in relation to short-term outcome in 118 prospectively studied Sudanese children who were admitted with meningococcal (MC) meningitis and/or septicaemia during the 1988 group A MC epidemic in Greater Khartoum are described. Their ages ranged from 25 days to 15 years (mean: 78 months) and 42% were less than 5 years old. The male:female ratio was 1.6:1. Forty (34%) came from one of the peri-urban shanty towns encircling Greater Khartoum. A history of MC immunization (A and C vaccine) was obtained in 22%, but only five children (4.8%) had the vaccine between 4 weeks and 1 year before their illness. The commonest symptoms on admission were vomiting, neck rigidity and diarrhoea. Convulsions were significantly more frequent in children under 5 years old (p = 0.0005). Fifty-six (47%) had evidence of malnutrition. In descending order, fever, neck stiffness and Kernig's sign were the most commonly observed signs, the latter two being significantly more often detected in children older than 1 year. Twenty-four patients 20%) had disturbed consciousness. The case fatality rate was 6.3% and this was significantly higher in those presenting with meningococcal septicaemia (p = 0.0006). Other significant associations with mortality were short duration (less than 1 day) of symptoms (p = 0.0006) and clinical shock detected on admission p = 0.003). Transient complications were infrequent and permanent neurological sequelae were confined to bilateral profound sensorineural hearing loss in three children (2.9%) and hemiplegia in two 1.9%.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M A Salih
- Department of Paediatrics, Faculty of Medicine, University of Khartoum
| | | | | | | | | | | | | |
Collapse
|
49
|
Salih MA, Ahmed HS, Karrar ZA, Kamil I, Osman KA, Palmgren H, Hofvander Y, Olcén P. Features of a large epidemic of group A meningococcal meningitis in Khartoum, Sudan in 1988. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1990; 22:161-70. [PMID: 2356440 DOI: 10.3109/00365549009037897] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A large epidemic (February-August 1988) of group A sulphonamide resistant, clone III-1 meningococcal meningitis in Khartoum, Sudan is described. A total of 10,099 cases were admitted to treatment centers with 8,397 cases during March and April, corresponding to an annual incidence of 1,679/100,000 inhabitants during this period. The age profile showed a high morbidity in adults (31% of the cases greater than or equal to 20 years). The male dominance was marked especially in the adult cases with a proportion of 3.2:1. The epidemic started during the hot and dry season and declined when the clouds came, humidity rose, temperature fell and a mass vaccination campaign had been implemented together with other epidemic precautions. Vaccination with a combined group A/C polysaccharide vaccine had been given 4 weeks-1 year before hospitalization to 11% of the children, 80% of whom were greater than 18 months of age. The estimated case fatality rate was 6.3%. Since 47% of the cases came from periurban and rural areas, the actual mortality during the epidemic might have been higher when considering those who may have died before reaching any of the treatment centres. Fatal cases had a short history of acute illness and a septic condition. Septicaemia was rare and seen in only 3.7% of the cases, the rest had acute purulent meningitis. Hearing loss/impairment and hemiplegia was diagnosed in 2-3% of the cases. The epidemiology, based on detailed typing/subtyping and restriction enzyme patterns of meningococcal strains, was apparently associated with the Mecca outbreak in August 1987.
Collapse
Affiliation(s)
- M A Salih
- Department of Paediatrics, Faculty of Medicine, University of Khartoum, Sudan
| | | | | | | | | | | | | | | |
Collapse
|
50
|
|